| 20.01 0 (0%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Singular Genomics Systems, Inc. is a life science technology firm focused on creating advanced next-generation sequencing and multiomics solutions. The company aims to provide researchers and clinicians with innovative tools to accelerate scientific discovery and medical advancements. Among its core products is the G4 Instrument, a compact next-generation sequencer designed to deliver genetic sequencing results, supported by a selection of complementary consumable kits. Singular Genomics also offers the PX Integrated Solution, a versatile multiomics platform that consolidates single-cell analysis, spatial analysis, genomics, and proteomics into a single, unified instrument. To ensure broad compatibility for the G4, the company maintains strategic partnerships with entities like Agilent Technologies, Dovetail Genomics, Lexogen, New England Biolab, QIAGEN, Roche, Twist Bioscience, and Watchmaker Genomics for the validation of their library preparation kits. Additionally, a collaboration with the Broad Institute of MIT and Harvard enables the G4's integration with the Terra data platform. Established in 2016, Singular Genomics Systems, Inc. is headquartered in La Jolla, California.
Thu, 24 Apr 2025
Singular Genomics Systems (OMIC) Stock Price, News & Analysis - Stock Titan
Tue, 18 Feb 2025
Singular Genomics Systems, Inc. Announces Merger with Deerfield-Backed Parent Company (OMIC Acquisition) - tradingcalendar.com
Thu, 16 Jan 2025
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OMIC, JWN, EDBL on Behalf of Shareholders - PR Newswire
Tue, 24 Dec 2024
Singular Genomics to be acquired by Deerfield for $20.00 per share in case - Yahoo Finance
Sat, 12 Oct 2024
StockWatch: Investors Unfazed by Illumina’s MiSeq Product Launches, Starboard’s $1B Stake in Pfizer - Genetic Engineering and Biotechnology News
Wed, 18 Sep 2024
Kevin Tang buys $1.8m in Singular Genomics Systems stock By Investing.com - Investing.com UK
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|